61MO Phase Ia/Ib study of the MDM2-p53 antagonist brigimadlin (BI 907828) in advanced solid tumours: Overall safety, and efficacy in patients (pts) with well-differentiated liposarcoma (WDLPS)
| Autor: | Reichardt, P., Schöffski, P., Lorusso, P., Yamamoto, N., Garcia, V. Moreno, Lugowska, I., Lauer, U., Somaiah, N., Hu, C., Landsteiner, H.T., Jayadeva, G., Gounder, M. |
|---|---|
| Zdroj: | In ESMO Open March 2024 9 Supplement 2 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|